Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

746 - Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) : Single center experience

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Jooyoung Ha

Citation

Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427

Authors

J. Ha1, J.E. Kim1, J.H. Jeong1, J. Ahn1, K.H. Jung1, H.J. Lee2, G. Gong2, E.Y. Chae3, H.H. Kim3, I.Y. Chung4, B.S. Ko4, S. Kim1

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Department Of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 3 Department Of Radiology And Research Institute Of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 4 Department Of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
More

Resources

Abstract 746

Background

Pathologic complete response (pCR) is known to be a predictive marker for favorable outcome after neoadjuvant treatment in HER2 positive (+) breast cancer. Our aim was to investigate the association between hormone receptor (HR) or tumor-infiltrating lymphocytes (TILs) and pCR in HER2 (+) breast cancer treated with dual anti-HER2 therapy.

Methods

Ninety-four patients with HER2 (+) breast cancer who received neoadjuvant treatment with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) were included in this retrospective analysis. Associations between TILs and pCR were assessed in the overall and hormone receptor (HR) positive (+) and HR negative (-) populations. We classified subgroups with a cutoff value of stromal TILs (≤20% TILs vs > 20% TILs) based on ROC curves.

Results

Of the 94 cases, 54 (57.4%) tumors achieved pCR (ypT0/is N0) and median TILs was 17.07% [13.81-20.65]. In analysis of hormone receptor, pCR was 51.0% (n = 26/51) in HR (+) group and 65.1% (n = 28/43) in HR (-) group (p = 0.167). The pCR rate was higher in the high TILs group than in the low TILs group (74.1% vs 51.4%, p = 0.038). In HR (-) group, high TILs and low TILs achieved 90% (n = 9/10) and 57.6% (n = 19/33) of pCR, respectively. In HR (+), pCR rates of high TILs and low TILs subgroups were 64.7% (n = 11/17) and 41.7% (n = 15/34).

Conclusions

In HER2 (+) breast cancer, HR (-) and high TILs showed higher pCR compared with HR(+) and low TILs. TILs might be a predictive marker for the treatment response to neoadjuvant dual anti HER2 based chemotherapy. Further investigation in a larger cohort of samples is needed to validate these results.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings